论文部分内容阅读
中国于1988年成功研制了日本脑炎减毒疫苗。自1989年以来,约有1.2亿年龄为1、2和6岁的中国儿童接种了SA 14-14-2日本脑炎减毒活疫苗。一项对照研究发现,两剂的有效率达98％。随后有报道单剂疫苗的功效亦高。本文目的在于验证此结论。 方法 尼泊尔自1978年以来发生超过17000例脑炎,其中4000例死亡,1～15岁年龄的儿童占62％。流行期始于7月季风雨期间,终于10月,近70％的病例发生于Bardiya,Banke和Kailali三个地区。1999年6月11日至24日,尼泊尔卫生部首次发起日本脑炎减毒活疫苗接种工作,对居住在上述三个地区的1～15岁儿童,皮下注射0.5mL日本脑炎减毒活疫苗(SA 14-14-2),共用160000剂量。疫苗均由中
In 1988, China successfully developed a Japanese encephalitis attenuated vaccine. About 120 million Chinese children aged 1, 2 and 6 years old have been vaccinated against live attenuated SA 14-14-2 Japanese immunization vaccine since 1989. A controlled study found that two doses of 98% efficiency. Subsequent reports of single-dose vaccine also have high efficacy. The purpose of this article is to verify this conclusion. Methods Nepal has had more than 17,000 cases of encephalitis since 1978, of which 4,000 died and 62% of children aged 1 to 15 years. The epidemic began during the July monsoon rains and finally in October, nearly 70% of the cases occurred in the three districts of Bardiya, Banke and Kailali. From June 11 to June 24, 1999, the Ministry of Health of Nepal launched the first live attenuated Japanese encephalitis vaccination campaign for Japanese encephalitis. Children aged 1-15 who live in these three regions were injected subcutaneously with 0.5 mL of live attenuated Japanese encephalitis vaccine (SA 14-14-2) sharing 160000 doses. Vaccine by the middle